Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update.
J Clin Endocrinol Metab. 2020 Mar 01;105(3): Authors: Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R
OBJECTIVE: The objective is to provide an update of the 2019 Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline for the pharmacological management of osteoporosis in postmenopausal women using romosozumab. CONCLUSIONS: We reviewed findings from the meta-analysis and primary clinical trials assessing the efficacy of romosozumab, a monoclonal antibody targeting sclerostin, for the prevention of fractures and concluded that this agent can be considered a treatment option for postmenopausal women at very high risk for osteoporotic fracture. The romosozumab label has a boxed warning, recommending careful consideration by the treating clinician as to cardiovascular risk profile in the individual woman who might receive this agent, since clinical trial data from an active comparator study show an imbalance in serious cardiovascular adverse events between romosozumab and alendronate. PMID: 32068863 [PubMed - in process]